Search results
Results from the WOW.Com Content Network
A translation between the Zubrod and Karnofsky scales that works especially well for healthy patients has been validated in a large sample of lung cancer patients: [4] Zubrod 0 equals Karnofsky 90–100; Zubrod 1 equals Karnofsky 70–80; Zubrod 2 equals Karnofsky 50–60; Zubrod 3 equals Karnofsky 30–40; Zubrod 4 equals Karnofsky 10–20
The diagnosis of brain metastases typically follows a diagnosis of a primary cancer. [10] ... the Karnofsky performance score is used for a more specific prognosis. [6]
For metastatic renal cell carcinoma, factors which may present a poor prognosis include a low Karnofsky performance-status score (a standard way of measuring functional impairment in patients with cancer), a low haemoglobin level, a high level of serum lactate dehydrogenase, and a high corrected level of serum calcium.
Increasing age (> 60 years) carries a worse prognostic risk. Death is usually due to widespread tumor infiltration with cerebral edema and increased intracranial pressure. [103] A good initial Karnofsky performance score (KPS) and MGMT methylation are associated with longer survival. [103]
SOFA was designed to provide a simple daily score, that indicates how the status of the patient evolves over time. Glasgow Coma Scale (also named GCS) is designed to provide the status for the central nervous system. It is often used as part of other scoring systems. FOUR score - 17-point scale for the assessment of level of consciousness. Aims ...
Manchester score is an indicator of prognosis in small cell lung cancer. [1] [2] It is calculated from a number of physical and biochemical markers. A patient with small cell lung cancer scores one point for each of the following: [citation needed] - Serum lactate dehydrogenase exceeds the upper limit of the reference range.
What links here; Related changes; Upload file; Special pages; Permanent link; Page information; Cite this page; Get shortened URL; Download QR code
The International Prognostic Index (IPI) is a clinical tool developed by oncologists to aid in predicting the prognosis of patients with aggressive non-Hodgkin's lymphoma. Previous to IPI's development, the primary consideration in assessing prognosis was the Ann Arbor stage alone, but this was increasingly found to be an inadequate means of ...